1. Home
  2. IAUX vs IOVA Comparison

IAUX vs IOVA Comparison

Compare IAUX & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo i-80 Gold Corp.

IAUX

i-80 Gold Corp.

HOLD

Current Price

$1.41

Market Cap

1.5B

Sector

N/A

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$3.33

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IAUX
IOVA
Founded
2020
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.4B
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
IAUX
IOVA
Price
$1.41
$3.33
Analyst Decision
Buy
Buy
Analyst Count
1
10
Target Price
$1.50
$9.11
AVG Volume (30 Days)
19.6M
15.6M
Earning Date
05-04-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
11.76
14.84
EPS
N/A
N/A
Revenue
$95,193,000.00
N/A
Revenue This Year
$116.98
$51.55
Revenue Next Year
$59.66
$37.55
P/E Ratio
N/A
N/A
Revenue Growth
89.12
N/A
52 Week Low
$0.48
$1.64
52 Week High
$2.24
$5.63

Technical Indicators

Market Signals
Indicator
IAUX
IOVA
Relative Strength Index (RSI) 37.47 41.08
Support Level $0.92 $2.02
Resistance Level $2.20 $4.34
Average True Range (ATR) 0.10 0.33
MACD -0.02 -0.14
Stochastic Oscillator 27.12 2.86

Price Performance

Historical Comparison
IAUX
IOVA

About IAUX i-80 Gold Corp.

i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Share on Social Networks: